SUPPLEMENTARY MATERIAL

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study

Diamant Thaçi¹, Andrea Bauer², Ralph von Kiedrowski³, Florian Schenck⁴, Konstantin Ertner⁵, Sophie Möller⁶, Anja Fait⁷, Mike Bastian⁷, Matthias Augustin⁸

¹Institute and Comprehensive Centre for Inflammatory Medicine, University of Luebeck, Luebeck, Germany
²Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany
³Company for Medical Study & Service Selters GmbH and Dermatology Practice Dr von Kiedrowski, Selters (Westerwald), Germany
⁴Hautärzte Zentrum Hannover, Hannover, Germany
⁵Hautarztpraxis Dr Ertner, Nürnberg, Germany
⁶Sanofi, Berlin, Germany
⁷Sanofi, Frankfurt, Germany
⁸Institute of Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Corresponding author:
Diamant Thaçi, Institute and Comprehensive Centre for Inflammatory Medicine, University of Luebeck, Ratzeburger Alee 160, 23538 Luebeck, Germany
Phone: +49 451 500 41600; Email: Diamant.Thaci@uksh.de
Supplementary Table 1: Family history of type 2 inflammatory diseases ($n=817$)

| Manifestation, %       | Yes    | No     | Missing/unknown |
|------------------------|--------|--------|-----------------|
| Allergic rhinitis      | 45.8   | 38.8   | 15.4            |
| Atopic dermatitis      | 40.4   | 46.3   | 13.3            |
| Asthma                 | 26.3   | 59.9   | 13.8            |
| Dust mite allergy      | 25.5   | 45.4   | 29.1            |
| Food allergy           | 24.9   | 50.3   | 24.8            |
| Nasal polyps           | 13.6   | 50.9   | 35.5            |

AD, atopic dermatitis.

Supplementary Table 2: Burden of disease (hospitalisations, exacerbations, and treatments) at baseline ($n=817$)

| Outcome                                                                 | Mean | SD  | Median | IQR     | $n$  |
|-------------------------------------------------------------------------|------|-----|--------|---------|------|
| Number of exacerbations experienced in the past 12 months               | 6.1  | 9.1 | 4.0    | 2.0–8.0 | 813  |
| Number of inpatient nights in the hospital in the past 24 months for the treatment of AD | 2.1  | 6.4 | 0      | 0–0     | 817  |
| Number of days in the day hospital in the past 24 months for the treatment of AD | 0.8  | 4.9 | 0      | 0–0     | 816  |
| Number of visits to the hospital outpatient department in the past 24 months for the treatment of AD | 1.1  | 3.5 | 0      | 0–0     | 817  |
| Number of days receiving UV therapy in the past 24 months              | 5.3  | 14.6| 0      | 0–1.0   | 814  |

AD, atopic dermatitis; IQR, interquartile range; $n$, number of patients; SD, standard deviation; UV ultraviolet.
Supplementary Table 3: Patient questionnaire at baseline: effort and financial burden due to AD (n = 817)

| Question                                                                 | Mean | SD   | Median | IQR       | n   |
|--------------------------------------------------------------------------|------|------|--------|-----------|-----|
| In the last 12 months, how many times did you visit a physician because of your AD? | 8.2  | 7.6  | 6.0    | 4.0–10.0  | 709 |
| How much money (€) do you spend every month in addition to the prescribed medications for the treatment of your AD? | 56.96| 58.22| 40.00  | 20.0–70.0 | 718 |

AD, atopic dermatitis; IQR, interquartile range; n, number of patients.
Supplementary Fig. 1: Age at baseline according to sex (categorical) ($n = 817$)

$n$, number of patients.
Supplementary Fig. 2 A) clinical eligibility criteria for systemic treatment\(^6\); B) recruited PROLEAD patients fulfilling checklist criteria (\(n = 817\))

A)

| Clinical eligibility criteria for systemic treatment | Yes | No |
|-----------------------------------------------------|-----|----|
| A: Relevant objective severity                       |     |    |
| - PGA of severity is at least three on the five-point scale, or | o   | o  |
| - EASI > 15 or                                       | o   | o  |
| - SCORAD >40/ oSCORAD >20 or                         | o   | o  |
| - Treatment-refractory affection of >10% of BSA or   | o   | o  |
| - Treatment-refractory eczema in sensitive/visible areas, or | o   | o  |
| - High-frequency of relapses (>10/year) with current treatment, or | o   | o  |

B: Relevant subjective burden

| Clinical eligibility criteria for systemic treatment | Yes | No |
|-----------------------------------------------------|-----|----|
| - DLQI >10, or                                       | o   | o  |
| - Pruritus >6 (on VAS or NRS ranging from 0–10) or   | o   | o  |
| - Relevant sleep disturbance at night due to eczema/pruritus | o   | o  |

C: Lack of treatment response

| Clinical eligibility criteria for systemic treatment | Yes | No |
|-----------------------------------------------------|-----|----|
| - No satisfactory response to topical or phototherapy or | o   | o  |
| - No expectation of success with topical measures alone or | o   | o  |
| Patient has already received one indicated systemic treatment unsuccessfully | o   | o  |
| - Contra-indication/no response/loss of efficacy/adverse events | o   | o  |

B)

![Graphic representation of patient distribution](image)

BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, eczema area and severity index; \(n\), number of patients; NRS, numeric rating scale; oSCORAD, objective-SCORAD; PGA, physician’s global assessment; SCORAD, scoring AD; VAS, visual analogue scale.